Your browser doesn't support javascript.
loading
Treatment of fibrotic interstitial lung disease: current approaches and future directions.
Johannson, Kerri A; Chaudhuri, Nazia; Adegunsoye, Ayodeji; Wolters, Paul J.
Afiliação
  • Johannson KA; Departments of Medicine and Community Health Sciences, Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada. Electronic address: kerri.johannson@ahs.ca.
  • Chaudhuri N; North West Lung Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK; Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.
  • Adegunsoye A; Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, IL, USA.
  • Wolters PJ; Department of Medicine, University of California, San Francisco, CA, USA.
Lancet ; 398(10309): 1450-1460, 2021 10 16.
Article em En | MEDLINE | ID: mdl-34499866
ABSTRACT
Fibrotic interstitial lung disease (ILD) represents a large group of pulmonary disorders that are often progressive and associated with high morbidity and early mortality. Important advancements in the past 10 years have enabled a better understanding, characterisation, and treatment of these diseases. This Series paper summarises the current approach to treatment of fibrotic ILDs, both pharmacological and non-pharmacological, including recent discoveries and practice-changing clinical trials. We further outline controversies and challenges, with discussion of evolving concepts and future research directions.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrose Pulmonar / Doenças Pulmonares Intersticiais Limite: Humans Idioma: En Revista: Lancet Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fibrose Pulmonar / Doenças Pulmonares Intersticiais Limite: Humans Idioma: En Revista: Lancet Ano de publicação: 2021 Tipo de documento: Article